Efficacy and safety evaluation of standardized management of hormone therapy in menopausal women

doi:10.3969/j.issn.1006-7795.2013.04.007

Abstract

Abstract:

Objective To evaluate efficacy and safety of standardized management of hormone therapy in menopausal women. Methods The menopausal women visited the endocrine clinic of Beijing Obstetrics and Gynecology Hospital affiliated to Capital Medical University after 2003 were divided into two group, hormone therapy and control group. There were 55 cases in hormone therapy group, and 34 cases in control group. We analyzed the variation of Kupperman sore, serum lipoprotein, resting energy expenditure, body fat, liver and renal function and mammary glands in the hormone therapy, so that assess the effectiveness and safety of hormone replacement therapy. Results 1 The Kupperman scores tended to decrease. 2 BMI did not change significantly in HT group and control group(P>0.05); BF% in the control group was significantly higher in the second year than the first year(P<0.05), while, compared with the first three years, the hormone therapy group BF% in the fourth year of treatment decreased significantly(P<0.05). Compared with the first year, REE/kg was reduced gradually in the second year in control group, however, REE/kg increased in HT group. 3 TC in control group increased gradually; LDL increased significantly in the second year(P<0.05). However, TC, TG and LDL-C were became lower gradually in HT group. 4 Liver and renal function was not significantly different during HT. The glands group of mammary gland between the first year and 5th year was not significantly different. Conclusion Hormone replacement therapy can relieve menopause-related symptoms; hormone therapy may alleviate abnormal blood lipids change in menopausal women; at the same time, it increases REE, eases the trend of BF% increase in menopausal women, so alleviates the progress of abdominal obesity after menopause, and to certain extent, it can reduce the risk of cardiovascular disease. During the standardized and individualized hormone therapy, the breast cancer risk is small.

Key words: menopause, hormone therapy, efficacy, safety

CLC Number:

R749.4⁺2

ZHANG Junli, RUAN Xiangyan, LIU Yulan, ZHEN Jie, YIN Dongmei, WANG Juan, LIU Shunyu. Efficacy and safety evaluation of standardized management of hormone therapy in menopausal women[J]. Journal of Capital Medical University, 2013, 34(4): 512-518.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2013.04.007

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2013/V34/I4/512

References

[1] Grady D, Applegate W, Bush T, et al. Heart and Estrogen/progestin Replacement Study(HERS): design, methods, and baseline characteristics[J]. Control Clin Trials, 1998,19(4):314-335.

[2] Fischer J. Nutrition and life style prevent myocardial infarct and stroke: 14 years follow-up of the US-American Nurses Health Study[J]. Praxis(Bem 1994), 2001,90(7):271-272.

[3] Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study[J]. Lancet, 2003,362(9382):419-427.

[4] Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up(HERS II)[J]. JAMA, 2002,288(1):49-57.

[5] Amuna P, Zotor F B. Epidemiological and nutrition transition in developing countries: impact on human health and development[J]. Proc Nutr Soc, 2008,67(1):82-90.

[6] Wu Z, Yao C, Zhao D. Sino-MONICA project: a collaborativestudy on trends and determinants in cardiovascular diseases in China, Part i: morbidity and mortality monitoring[J]. Circulation, 2001,103 (3):462-468.

[7] Pearson T A. New tools for coronary risk assessment: what are their advantages and limitations[J]. Circulation, 2002,105(7):886-892.

[8] Yang Z J, Liu J, Ge J P, et al. Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and Metabolic Disorders Study[J]. Eur Heart J, 2012,33(2):213-220.

[9] 任晓红,孙英贤,李晓东,等.性急性心肌梗死患者临床及冠脉造影特点分析[J].中国医科大学学报,2010,39(4):298-300.

[10] He L,Tang X, Li N, et al. Menopause with cardiovascular disease and its risk factors: among rural Chinese women in Beijing: a population-based study[J]. Maturitas, 2012,72(2):132-138.

[11] Matthews K A, Crawford S L, Chae C U, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?[J]. J Am Coll Cardiol, 2009,54(25):2366-2373.

[12] Lamon-Fava S, Herrington D M, Horvath K V, et al. Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status[J]. Metabolism, 2010,59(12):1794-1800.

[13] British Cardiac Society, British Hypertension Society, Diabetes UK, et al. JBS 2: Joint British Societies guidelines on prevention of cardiovascular disease in clinical practice[J]. Heart, 2005,91(Suppl 5):v1-v52.

[14] Kwok S, Canoy D, Soran H, et al. Body fat distribution in relation to smoking and exogenous hormones in British women[J]. Clin Endocrinol(Oxf), 2012,77(6):828-833.

[15] McTigue K, Larson J C, Valoski A, et al. Mortality and cardiac and vascular outcomes in extremely obese women[J]. JAMA, 2006,296(1):79-86.

[16] Adams K F, Schatzkin A, Harris T B, et al.Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old[J]. N Engl J Med, 2006,355(8):763-778.

[17] Flegal K M, Graubard B I, Williamson D F, et al. Cause-specific excess deaths associated with underweight, overweight, and obesity[J]. JAMA, 2007,298(17):2028-2037.

[18] Kwok S, Canoy D, Soran H, et al. Body fat distribution in relation to smoking and exogenous hormones in British women[J]. Clin Endocrinol(Oxf), 2012,77(6):828-833.

[19] Larsson B, Svardsudd K, Welin L, et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913[J]. Br Med J(Clin Res Ed), 1984,288(6428):1401-1404.

[20] Seeger H, Mueck A O. Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data[J]. J Steroid Biochem Mol Biol, 2008,109(1-2):11-15.

[21] Margolis K L, Bonds D E, Rodabough R J, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial[J]. Diabetologia, 2004,47(7):1175-1187.

[22] Stefanick M L, Anderson G L, Margolis K L, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy[J]. JAMA, 2006,295(14):1647-1657.

[23] de Villiers T J, Gass M L, Haines C J, et al. Global Consensus Statement on menopausal hormone therapy[J]. Maturitas, 2013,74(4):391-392.

[24] Mueck A O, Seeger H. The World Health Organization defines hormone replacement therapy as carcinogenic-is this plausible?[J]. Gynecol Endocrinol, 2008,24(3):129-132.

[25] 马骏,傅继华.生活方式与乳腺癌发病相关性的研究进展[J].中华肿瘤防治杂志,2012,19(5):397-400.

[26] Aguilar Cordero MJ, Neri Sánchez M, Padilla López CA, et al. Overweight/obesity in women and its implication in breast cancer: age of diagnosis[J]. Nutr Hosp, 2012,27(5):1643-1647.

[27] Hulka B, Moorman P G. Breast cancer: hormones and other risk factors[J]. Maturitas, 2008,61(1-2):203-213.

[28] Cummings S R, Tice J A, Bauer S. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk[J]. J Natl Cancer Inst, 2009,101(6):384-398.